These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 36297518)

  • 1. Proposal to Consider Chemical/Physical Microenvironment as a New Therapeutic Off-Target Approach.
    Giuliani A; Fais S
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nonmainstream approach against cancer.
    Fais S
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):882-9. PubMed ID: 26972280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering?
    Spugnini E; Fais S
    Semin Cancer Biol; 2017 Apr; 43():111-118. PubMed ID: 28088584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors.
    Spugnini EP; Fais S
    Expert Opin Ther Pat; 2020 Jan; 30(1):15-25. PubMed ID: 31847622
    [No Abstract]   [Full Text] [Related]  

  • 6. Proton channels and exchangers in cancer.
    Spugnini EP; Sonveaux P; Stock C; Perez-Sayans M; De Milito A; Avnet S; Garcìa AG; Harguindey S; Fais S
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2715-26. PubMed ID: 25449995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based support for the use of proton pump inhibitors in cancer therapy.
    Fais S
    J Transl Med; 2015 Nov; 13():368. PubMed ID: 26597250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor acidity, chemoresistance and proton pump inhibitors.
    De Milito A; Fais S
    Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy.
    Iessi E; Logozzi M; Mizzoni D; Di Raimo R; Supuran CT; Fais S
    Metabolites; 2017 Dec; 8(1):. PubMed ID: 29295495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Computational Approach to Predict Off-Target Interactions for Small Molecules.
    Rao MS; Gupta R; Liguori MJ; Hu M; Huang X; Mantena SR; Mittelstadt SW; Blomme EAG; Van Vleet TR
    Front Big Data; 2019; 2():25. PubMed ID: 33693348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.
    Timmons JA; Anighoro A; Brogan RJ; Stahl J; Wahlestedt C; Farquhar DG; Taylor-King J; Volmar CH; Kraus WE; Phillips SM
    Elife; 2022 Jan; 11():. PubMed ID: 35037854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.
    Harguindey S; Arranz JL; Polo Orozco JD; Rauch C; Fais S; Cardone RA; Reshkin SJ
    J Transl Med; 2013 Nov; 11():282. PubMed ID: 24195657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing.
    Lim H; Poleksic A; Yao Y; Tong H; He D; Zhuang L; Meng P; Xie L
    PLoS Comput Biol; 2016 Oct; 12(10):e1005135. PubMed ID: 27716836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-infective properties of proton pump inhibitors: perspectives.
    da Rosa TF; Foletto VS; Serafin MB; Bottega A; Hörner R
    Int Microbiol; 2022 Jan; 25(1):217-222. PubMed ID: 34476634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
    Palve V; Liao Y; Remsing Rix LL; Rix U
    Semin Cancer Biol; 2021 Jan; 68():209-229. PubMed ID: 32044472
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.